Abdominal fat, which is the most dangerous type metabolically, shows the most dramatic reduction
Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers Gobburu JV, Agers H, Jusko WJ, Ynddal L Pharmaceutical Research (1999) This PK/PD study in human volunteers documented Ipamorelin's pharmacokinetic profile, showing peak GH concentrations approximately 30-40 minutes post-injection with effects lasting 2-3 hours
Paulsen, 2024)
By activating both, it boosts insulin release, lowers glucagon levels, slows digestion, and promotes a sense of fullness
Lin C, Loke WH, Ng BH, Chin YH, Chong B, Goh RSJ, et al
We used an mGIPR-Ab that fully neutralizes GIPR activity in vitro and prevents body weight gain in obese mice when dosed systemically 17